Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
02 avr. 2024 07h30 HE
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
28 mars 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
27 mars 2024 08h00 HE
|
PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
PharmAla Biotech Signs Sale Agreement with Numinus
26 mars 2024 08h55 HE
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
26 mars 2024 07h30 HE
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20 mars 2024 10h20 HE
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18 mars 2024 08h55 HE
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
08 mars 2024 16h15 HE
|
PharmAla Biotech
PharmAla provides corporate update following AGM
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
28 févr. 2024 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...
PharmAla named an Intellectual Property Ontario Client
22 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.